Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
An open-label, non-randomized, phase II study to assess the safety and efficacy of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Cell Carcinoma patients
Detailed description
PRIMARY OBJECTIVES: To determine the R0 resection rate of Borderline Resectable Esophageal Squamous Cell Carcinoma patients who used preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin SECONDARY OBJECTIVES: To evaluate the Pathological Complete Response (pCR) rate, Progression Free Survival (PFS), Relapse Rate, Tumor Regression Grading (TRG) post preoperative chemotherapy, Overall Survival (OS), safety and toxicity of chemotherapy regimen and surgery. EXPLORATORY OBJECTIVES: Exploring the benefits of this treatment strategy in Borderline Resectable Esophageal Squamous Cell Carcinoma patients at a molecular level OUTLINE: Eligible patients receive Sintilimab and cisplatin intravenously on day 1 and albumin-bound paclitaxel intravenously on days 1 and 8. This cycle is repeated every 3 weeks in the absence of disease progression or unacceptable toxicity. Radiological and multidisciplinary assessment is performed after every 2-4 cycles.
Interventions
DRUGSintilimab
Route of administration: Intravenous
DRUGNab paclitaxel
Route of administration: Intravenously over 30min
DRUGCisplatin
Route of administration: Intravenous
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
CSPC Pharmaceutical Group Limited
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must provide a signed Informed Consent Form 2. Age ≥18 years old 3. Histological confirmation of T4N0-3M0 thoracic esophageal squamous cell carcinoma, absence of distant metastasis and confirmation of a borderline resectable lesion after multidisciplinary assessment using enhanced CT and/or Endoscopic Esophageal Ultrasound or Endobronchial Ultrasound. The definition of a borderline resectable lesion includes: CT showing that the fat gap between the tumor and the aorta is blurred, the angle between three contiguous planes (2mm/layer) and the aorta exceeds 90 degrees; or Endoscopic Esophageal Ultrasound revealing that the tumor has invaded the adventitia layer of the esophagus, and the boundary with the aorta is unclear; or Endobronchial Ultrasound showing an unclear border between the tumor and trachea or bronchus, but has yet invaded the trachea or bronchial mucosa or submucosa 4. Patients have not received any anti-tumor treatment for esophageal cancer (including surgery, chemotherapy, interventional therapy, immunotherapy, radiotherapy, etc.) 5. Life expectancy ≥3 months 6. General physical status (ECOG PS score) 0-1 points 7. Blood routine test (within 7 days): Hb ≥9g/L, NE ≥1.5×109/L, PLT ≥90×109/L 8. Liver and kidney function test (within 7 days): total bilirubin ≤1.5 UNL, creatinine ≤1.5× UNL, AST /ALT ≤2.5xUNL, ALP ≤5.0xUNL 9. No serious complications such as active gastrointestinal bleeding, perforation, jaundice, intestinal obstruction, fever unrelated to malignant disease\>38℃ 10. Patients with reproductive potential should take effective contraceptive measures 11. Patients with good compliance and that can attend scheduled follow up to assess the efficacy and adverse reactions of the treatment
Exclusion criteria
1. Patients with cervical esophageal squamous cell carcinoma 2. Patients with distant metastases 3. Patients with a high risk of complete esophageal obstruction and require interventional therapy 4. Patients with stent implantation in the esophagus or trachea 5. Patients with an esophageal tumor that invaded adjacent organs (aorta or trachea), causing an increased risk of bleeding or perforation, or patients with a fistula 6. Concurrent primary cancers (except for cured skin basal cell carcinoma and cervical carcinoma in situ) 7. History of immunosuppressive drug use within 1 week before treatment, excluding nasal spray, inhalation or use of local glucocorticoids or physiological doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone or equivalent doses of other glucocorticoids) or glucocorticoids used to prevent contrast agent allergy. 8. Patients with active or a past history (within 2 years) of autoimmune disease that need symptomatic treatment (Patient diagnosed with vitiligo, psoriasis, alopecia, or Grave disease that did not require systemic treatment within the past 2 years, hypothyroidism that requires only thyroid hormone replacement therapy and type I diabetes patients treated with insulin replacement therapy only are eligible) 9. Patients with a history of primary immunodeficiency disease 10. Patients with a history of active tuberculosis 11. Patients with a past history of allogenic organ transplantation and allogeneic hematopoietic stem cell transplantation 12. Patients diagnosed with interstitial lung disease that require steroid therapy 13. Patients with a known history of allergy to any monoclonal antibody or chemotherapeutic drugs (taxanes, cisplatin) or their constituents. 14. Patients with a history of severe heart disease, including: history of congestive heart failure, patients with high-risk of uncontrolled arrhythmias, angina pectoris requiring medical treatment, clinically diagnosed heart valve disease, history of severe myocardial infarction and refractory hypertension 15. Patients with chronic diarrhea (4 or more watery stools per day) and patient with renal insufficiency 16. Patients with an active infection or an active infectious disease 17. Neurological or mental disorders that affect cognitive ability 18. Pregnant or breastfeeding women 19. Other acute or chronic diseases, mental diseases or laboratory test values that may cause the following abnormal outcomes: Increase participants or drug administration related risks, interfere with the interpretation of the study results, and patients deemed as ineligible to participate in the study based on the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate of patients who underwent surgery following preoperative treatment | up to 28 weeks | The proportion of people with a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival from the date of first drug administration until the date of first documented progression or date of death, whichever came first. | up to 28 weeks | The length of time during and after the treatment of the disease, that a patient lives with the disease without its aggravation |
| Tumor regression rate of patients following preoperative treatment | immediately before surgery | A decrease in the size of a tumor or the extent of cancer in the body |
| Pathological complete response rate of patients who received surgery following preoperative treatment | up to 28 weeks | The proportion of patients showing an absence of invasive/in situ cancer after treatment |
| Overall survival from the date of first drug administration until the date of death from any cause | up to 28 weeks | The length of time from the start of treatment that patients diagnosed are still alive |
| Number of patients with adverse events and severity according to NCI CTCAE v5.0 | up to 28 weeks | Summary of the Adverse events experienced during treatment related to the drug used or surgery in this study |
| Relapse rate of patients who received surgery following preoperative treatment | up to 28 weeks | The number of people with deterioration or recurrence of cancer after a temporary improvement |
Countries
China
Outcome results
None listed